GERN Key Statistics, Chart & Performance
The current stock price of GERN is 1.595 USD. In the past month the price increased by 11.68%. In the past year, price decreased by -47.78%.
GERN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GERN. When comparing the yearly performance of all stocks, GERN is a bad performer in the overall market: 70.03% of all stocks are doing better.
GERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GERN. GERN may be in some trouble as it scores bad on both profitability and health.
GERN Financial Highlights
Over the last trailing twelve months GERN reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 62.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.04% | ||
| ROE | -32.02% | ||
| Debt/Equity | 0.92 |
GERN Forecast & Estimates
13 analysts have analysed GERN and the average price target is 3.23 USD. This implies a price increase of 102.51% is expected in the next year compared to the current price of 1.595.
For the next year, analysts expect an EPS growth of 57.19% and a revenue growth 150.41% for GERN
GERN Ownership
GERN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.29 | 394.886B | ||
| AMGN | AMGEN INC | 16.69 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.02 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.79 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.61 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GERN
Company Profile
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Company Info
GERON CORP
919 East Hillsdale Boulevard, Suite 250
Foster City CALIFORNIA 94404 US
CEO: John A. Scarlett
Employees: 229
Phone: 16504737700
GERON CORP / GERN FAQ
Can you describe the business of GERON CORP?
Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Can you provide the latest stock price for GERON CORP?
The current stock price of GERN is 1.595 USD. The price increased by 4.25% in the last trading session.
Does GERON CORP pay dividends?
GERN does not pay a dividend.
What is the ChartMill rating of GERON CORP stock?
GERN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of GERN stock?
GERON CORP (GERN) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of GERON CORP (GERN) based on its PE ratio?
GERON CORP (GERN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
What is the Short Interest ratio of GERON CORP (GERN) stock?
The outstanding short interest for GERON CORP (GERN) is 11.1% of its float.